Effects of human parathyroid hormone (1-34), LY333334, on bone mass, remodeling, and mechanical properties of cortical bone during the first remodeling cycle in rabbits.

Mashiba T, Burr DB, Turner CH, Sato M, Cain RL, Hock JM

Bone1 May 2001Cited by 59 (Europe PMC)

PMID11344054DOI10.1016/s8756-3282(01)00433-1PepBankPUB-11344054

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rabbits, PTH increased intracortical activation frequency versus vehicle at 35 days.
In plain wordsIn rabbits, PTH increased intracortical activation frequency compared with vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseIntracortical activation frequency
Study
rabbitn: not reported in source
Intact female New Zealand white rabbits
Comparator
Age-matched vehicle controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
10 microg/kg daily · subcutaneous · 35 daysAs given in this study (rabbit).
Source sentences
Summary
Histomorphometry of the cortical bone in the tibial midshaft showed that, although intracortical activation frequency was significantly increased by PTH at 35 days, there was no significant increase of cortical porosity in the first remodeling cycle (70 days).
1 context sentence(design, population, supporting numbers)
Summary · context
The two PTH-treated groups were given human PTH(1-34) at 10 microg/kg daily subcutaneously for 35 (P35) or 70 (P70) days. Two respective age-matched control groups (V35, V70) were injected with vehicle.
Report a problemFND-1134405401
02AnimalAnimal study (in vivo)Efficacy outcome
In rabbits, PTH did not significantly increase cortical porosity during the first remodeling cycle versus vehicle.
In plain wordsIn rabbits, PTH did not significantly increase cortical porosity compared with vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeCortical porosity
Study
rabbitn: not reported in source
Intact female New Zealand white rabbits
Comparator
Age-matched vehicle controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
10 microg/kg daily · subcutaneous · 70 daysAs given in this study (rabbit).
Source sentences
Summary
Histomorphometry of the cortical bone in the tibial midshaft showed that, although intracortical activation frequency was significantly increased by PTH at 35 days, there was no significant increase of cortical porosity in the first remodeling cycle (70 days).
1 context sentence(design, population, supporting numbers)
Summary · context
The two PTH-treated groups were given human PTH(1-34) at 10 microg/kg daily subcutaneously for 35 (P35) or 70 (P70) days. Two respective age-matched control groups (V35, V70) were injected with vehicle.
Report a problemFND-1134405402
03AnimalAnimal study (in vivo)Efficacy outcome
In rabbits, PTH increased cortical area versus vehicle at both treatment times.
In plain wordsIn rabbits, PTH increased cortical area compared with vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCortical area
Study
rabbitn: not reported in source
Intact female New Zealand white rabbits
Comparator
Age-matched vehicle controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
10 microg/kg daily · subcutaneous · 35 and 70 daysAs given in this study (rabbit).
Source sentences
Summary
Moreover, stimulation of cortical surface bone formation in the treated animals led to significantly greater cortical area and greater bone strength in both P35 and P70.
1 context sentence(design, population, supporting numbers)
Summary · context
The two PTH-treated groups were given human PTH(1-34) at 10 microg/kg daily subcutaneously for 35 (P35) or 70 (P70) days. Two respective age-matched control groups (V35, V70) were injected with vehicle.
Report a problemFND-1134405403
04AnimalAnimal study (in vivo)Efficacy outcome
In rabbits, PTH increased cortical bone strength versus vehicle at both treatment times.
In plain wordsIn rabbits, PTH increased cortical bone strength compared with vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCortical bone strength
Study
rabbitn: not reported in source
Intact female New Zealand white rabbits
Comparator
Age-matched vehicle controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
10 microg/kg daily · subcutaneous · 35 and 70 daysAs given in this study (rabbit).
Source sentences
Summary
Moreover, stimulation of cortical surface bone formation in the treated animals led to significantly greater cortical area and greater bone strength in both P35 and P70.
1 context sentence(design, population, supporting numbers)
Summary · context
The two PTH-treated groups were given human PTH(1-34) at 10 microg/kg daily subcutaneously for 35 (P35) or 70 (P70) days. Two respective age-matched control groups (V35, V70) were injected with vehicle.
Report a problemFND-1134405404
05AnimalAnimal study (in vivo)Efficacy outcome
In rabbits, PTH stimulated cortical surface bone formation compared with vehicle.
In plain wordsIn rabbits, PTH increased bone formation on cortical surfaces compared with vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCortical surface bone formation
Study
rabbitn: not reported in source
Intact female New Zealand white rabbits
Comparator
Age-matched vehicle controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
10 microg/kg daily · subcutaneous · 35 or 70 daysAs given in this study (rabbit).
Source sentences
Summary
Moreover, stimulation of cortical surface bone formation in the treated animals led to significantly greater cortical area and greater bone strength in both P35 and P70.
1 context sentence(design, population, supporting numbers)
Summary · context
The two PTH-treated groups were given human PTH(1-34) at 10 microg/kg daily subcutaneously for 35 (P35) or 70 (P70) days. Two respective age-matched control groups (V35, V70) were injected with vehicle.
Report a problemFND-1134405405

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.